Novartis $2 million gene therapy for rare disorder is world's most expensive drug
ZURICH/NEW YORK - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.
from Reuters: Health News https://reut.rs/2WqEyth
http://bit.ly/2zwRqiM